Nrx pharmaceuticals files provisional patent for stable compositions of aviptadil suitable for human use

Radnor, pa., jan. 3, 2022 /prnewswire/ -- nrx pharmaceuticals (nasdaq: nrxp) announced today that it has filed a provisional composition of matter patent application with the us patent and trademark office entitled "stable, buffer-free compositions of vasoactive intestinal peptide (vip).
NRXP Ratings Summary
NRXP Quant Ranking